1. Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia, Even with a Higher Leukemia Burden 
Wei-Ping Zhang, Dan Yang, Xian-Min Song, Xiong Ni, Jie Chen, Li Chen, Jian-min Yang, Hong Zhou, Hui Cheng, Bao-hai Liu, Hong-Mei Li, Jian-Min Wang 
Biology of Blood and Marrow Transplantation 
Volume 19, Issue 4, Pages (April 2013)
DOI: /j.bbmt
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
(A) Overall survival and (B) event-free survival of 58 patients with refractory/relapsed acute myelogenous leukemia and 66 patients with non–refractory/relapsed acute myelogenous leukemia.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) Relapse rate and (B) transplant-related mortality of 58 patients with refractory/relapsed acute myelogenous leukemia and 66 patients with non–refractory/relapsed acute myelogenous leukemia.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
The probability of overall survival (A), event-free survival (B), relapse (C), and transplant-related mortality (D) in refractory/relapsed acute myelogenous leukemia patients with CR or NR disease status before transplantation.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions